Theratechnologies (TSE:TH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theratechnologies has announced an FDA review date for its new tesamorelin formulation, F8, set for March 2025. If approved, this formulation will replace the current F4 version and enjoys patent protection in the U.S. until 2033. The development could impact the company’s stock performance, attracting investor attention.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.